WOW scripts...RBC update..Very Stable..Plaquenil AG TRx down 0.1% WoW, underperforms broader market. Plaquenil AG (Prasco) TRx were down 0.1% WoW vs. down 0.2% the prior week. Total hydroxychloroquine (broader plaquenil market) TRxs up down 0.5% WoW and Prasco's market share (Concordia AG) currently sits at 38.4% of TRx vs. 38.7% the prior week. We have outlined Plaquenil/ hydroxychloroquine market share trends in Exhibit 2. As previously noted, we believe Plaquenil AG pricing decreased by ~40% in early Q3 and we note that Concordia confirmed that Plaquenil AG is seeing further pricing pressure due to the Actavis generic (1.9% market share).
Lanoxin AG TRx up 1.2% WoW. Par's (AG) market share was up slightly to 32.1% from 31.8%, Sun Pharma's market share decreased from 9.1% to 8.4% this week, WestWard Pharma's share increased from 9.0% to 9.4%, Digoxin saw its share decrease from 25.5% to 25.1%, and Impax's share increased slightly to 24.5% from 23.4%. The Lanoxin AG (Par Pharma) saw TRx increase 1.2% WoW vs. a 4.1% decrease last week. The broader market saw TRx flat WoW. We have outlined Lanoxin/Digoxin market trends in Exhibit 3.
Donnatal TRx up 0.6% WoW. As previously noted, we have been monitoring the market share of several IBS drugs that target both IBS-C and IBS-D, due to the launch of Allergan's Viberzi in December (TRx up 2.8% WoW). While Donnatal saw a slow decline in scripts between January and August, we believe market share is beginning to stabilize. Donnatal NRx were up 5.3% WoW vs. down 2.7% the prior week and TRx were up 0.6% WoW vs. down 1.1% the prior week. Donnatal's current market share (TRx) is 1.7%; Xifaxan holds a 15.7% market share, Viberzi has a 4.3% share, Amitiza has a 26.9% share, and Linzess has a 51.1% share. Exhibit 5 shows Donnatal weekly NRx and TRx trends.
Other CXRX products: Nilandron TRx down 10.0% WoW, Dibenzyline AG TRx down 13.8% WoW, and Kapvay TRx up 16.1% WoW. Nilandron saw TRx of 27, down 10.0% WoW. We note that ANI Pharmaceuticals had a generic version of Nilandron approved by the FDA on July 18. The ANI generic saw TRx decrease 22.9% WoW to 27 TRxs. We anticipate that CXRX will launch an AG before year-end.